Top

Published in:

01-02-2019 | Metastasis | Review Article

History of Peritoneal Surface Malignancy Treatment in Japan

Authors: Yutaka Yonemura, Shouzou Sako, Satoshi Wakama, Haruaki Ishibashi, Akiyoshi Mizumoto, Nobuyuki Takao, Masumi Ichinose, Kousuke Noguchi, Yang Liu, Syunsuke Motoi, Keizou Taniguchi, Sachio Fushida

Published in: Indian Journal of Surgical Oncology | Special Issue 1/2019

Abstract

In this review, Japanese experience of cytoreductive surgery and perioperative chemotherapy is described. The new concept of peritoneal metastasis (PM) type, i.e., trans-mesothelial, trans-lymphatic, and superficial growing metastasis type was proposed in 2012. Surgeons should perform peritonectomy according to the type of PM. Since 1980, Japanese surgical oncologists have been spearheading the use of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemoperfusion (HIPEC) as treatment for PM from gastric cancer. Two RCTs were conducted to verify the effect of HIPEC for the prophylaxis of peritoneal recurrence after curative resection of advanced gastric cancer. These two studies indicated that HIPEC is effective in preventing peritoneal recurrence of gastric cancer with serosal invasion. In 2002, intraperitoneal chemotherapy using taxans was developed for the treatment of PM from gastric cancer and led to the development of neoadjuvant intraperitoneal/systemic chemotherapy (NIPS), which was reported in 2006. In 2009, extensive intra-operative peritoneal lavage (EIPL) was developed, and contributed to the remarkable improvement in survival of patients with positive lavage cytology as demonstrated by prospective randomized clinical trials. In 2017, the Peritoneal Surface Oncology Group International proposed the value of complete cytoreduction and peritoneal cancer index cut-off as independent prognostic factors after CRS for gastric cancer with PM. Founded in 2016, the Japanese/Asian School of Peritoneal Surface Oncology (JASPSO) trains beginners to perform CRS and HIPEC safely. Sixteen students have already graduated from JASPSO and started to perform the treatment in their home countries.

Chu DZ, Lang NP, Thompson C et al (1989) Peritoneal carcinomatosis in nongynecological malignancy. Cancer 63:364–367CrossRefPubMed

Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Brit J Surg 89:1545–1550CrossRefPubMed

Spratt JS, Adcock RA, Muskovin M et al (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40(2):256–260PubMed

Alexander HR, Fraker DL (1996) Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin. Cancer Treat Res 81:41–50CrossRefPubMed

Franko J, Shi Q, Goldman CD et al (2012) Treatment of colorectal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trial N9741 and N9841. Cancer Res 30(3):263–267. https://doi.org/10.1200/JCO.2011.37.1039 CrossRef

Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42CrossRefPubMedPubMedCentral

Verwaal VJ, Bruin A, Boot H et al (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15(9):2426–2432. https://doi.org/10.1245/s10434-008-9966-2 CrossRefPubMed

Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P et al (2015) Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systemic review and meta-analysis. EJSO. https://doi.org/10.1016/j.ejso.2015.03.231

Glehen O, Gilly FN, Arvieux C et al (2010) Peritoneal carcinomatosis from gastric cancer A muti-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377. https://doi.org/10.1245/s10434-010-1039-7 CrossRefPubMed

10.

Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18:1575–1581CrossRefPubMedPubMedCentral

11.

Yonemura Y (2018) Peritoneal cancer index and prognosis. In: Yonemura Y (ed) Comprehensive treatment for peritoneal surface malignancy with an intent of cure. NPO to Support Peritoneal Surface Malignancy, pp 3–55

12.

Jayne D (2007) Molecular biology of peritoneal carcinomatosis. In: Ceelen WP (ed) Cancer treatment and research. Springer, pp 21–31

13.

Yonemura Y, Canbay E, Liu Y et al (2013) Trans-lymphatic metastasis in peritoneal dissemination. J Gastroint Dig Syst S12. https://doi.org/10.4172/2161-069X.S12-007

14.

Sugarbaker PH (1997) Observation concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: a multidisciplinary approach. Kluwar Academic Publisher, Boston, pp 79–100

15.

Yonemura Y (2012) Trans-lymphatic metastasis. In: Yonemura Y (ed) Atlas and principles of peritonectomy for peritoneal surface malignancy, Published by NPO to Support Peritoneal Surface Malignancy, pp 188–206

16.

Bettendorf U (1978) Lymph flow mechanism of the subperitoneal diaphragmatic lymphatics. Lymphology 11(3):111–116PubMed

17.

Tsujimoto H, Takhashi T, Hagiwara A et al (1995) Site-specific implantation in the milky spots of malignant cells in peritoneal dissemination: immunohistochemical observation in mice inoculated intraperitoneally with bromodeoxyuridine-labeled cells. Br J Cancer 71:468–472CrossRefPubMedPubMedCentral

18.

Shimotsuma M, Takahashi T, Kawata M, Dux K (1991) Cellular subset of the milky spots in the human greater omentum. Cell Tissue Res 264:599–601CrossRefPubMed

19.

Diaz-Flores L, Gutierrez R, Garcia MP et al (2014) CD34+ stromal cells/fibroblastis/fibrocytes/telocyted as a tissue reserve and principal source of mesenchymal cells. Location, morphology, function and role in pathology. Histol Histopathol 29:831–870PubMed

20.

Koga S, Shimizu N, Maeta M, Hamazoe R, Izumi A (1983) Application of heat combined with antineoplastic agent administration in the treatment if cancer (with special reference to malignancy of the digestive system). Gan to Kagaku Ryoho 10:358–365PubMed

21.

Fujimura T, Yonemura Y, Fushida S, Urade M, Takegawa S, Kamata T, Sugiyama K, Hasegawa H, Katayama K, Miwa K, Miyazaki I (1990) Continuous hyperthermic intraperitoneal perfusion for the treatment of peritoneal dissemination in gastric cancer and subsequent second-look operation. Cancer 65(1):65–71CrossRefPubMed

22.

Yamaguchi A, Tsukioka Y, Fushida S, Kurosaka Y, Kanno M, Yonemura Y, Miwa K, Miyazaki I (1992) Intraperitoneal hyperthermic treatment for peritoneal dissemination of colorectal cancer. Dis Colon Rectum 35(10):964–968CrossRefPubMed

23.

Fujimoto S, Takahashi M, Mutou T et al (1996) Survival time and prevention of side effects of intraperitoneal perfusion with mitomycin C combined with surgery for patients with advanced gastric cancer. Cancer Treat Res 81:169–176CrossRefPubMed

24.

Yonemura Y, Fujimura T, Fushida S, Takegawa S, Kamata T, Katayama K, Kosaka T, Yamaguchi A, Miwa K, Miyazaki I (1991) Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg 15(4):530–535CrossRefPubMed

25.

Fushida S, Furui N, Kinami S et al (2002) Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination. Gan To Kgaku Ryoho 29(12):2164–2167 (in Japanese)

26.

Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, Sugarbaker PH (2006) Neoadjuvant treatment of gastric cancer with peritoneal dissemination. EJSO 32(6):661–665CrossRefPubMed

27.

Yonemura Y, Endou Y, Sasaki T et al (2010) Surgical treatment for peritoneal carcinomatosis from gastric cancer. EJSO 36(12):1121–1138CrossRef

28.

Yonemura Y, Canbay E, Li Y et al (2016) A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol available in online. https://doi.org/10.1016/j.ejso.2016.03.016

29.

Yonemura Y, Ayman E, Endou Y et al (2012) Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol 2012:148420. https://doi.org/10.1155/2012/148420 CrossRefPubMedPubMedCentral

30.

Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P, Ceresoli M, Montori G, Ansaloni L (2016) Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis. Eur J Surg Oncol 42(9):1261–1267. https://doi.org/10.1016/j.ejso.2016.03.035 ReviewCrossRefPubMed

31.

Valle M, Van der Speeten K, Garofalo A (2009) Laparoscopic hyperthermic intraperitoneal preoperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol 100(4):331–334. https://doi.org/10.1002/jso.21321 CrossRefPubMed

32.

Yonemura Y, Elnemr A, Endou Y, Ishibashi H, Mizumoto A, Miura M, Li Y (2012) Surgical results of patients with peritoneal carcinomatosis treated with cytoreductive surgery using a new technique named aqua dissection. Gastroenterol Res Pract 2012:521487. https://doi.org/10.1155/2012/521487 CrossRefPubMedPubMedCentral

33.

Hong SH, Shin YR, Roh Y, Jeong EK, Song KY, Park CH et al (2013) Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center. Gastric Cancer 16:290–300. https://doi.org/10.1007/s10120-012-0182-1 CrossRefPubMed

34.

Koh JL, Yan TD, Glenn D, Morris DL (2009) Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 16:327–333. https://doi.org/10.1245/s10434-008-0234-2 CrossRefPubMed

35.

Pôfannenberg C, Knigstainer, Aschoff P, Oksűz MO, Zieker D, Beckers S et al (2009) (18) F-FDG-PET-CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 16:1295–1303CrossRef

36.

Thomas F, Ferron G, Gesson-Paute A, Hristova M, Lochon I, Chatelut E (2008) Increased tissue diffusion of oxaliplatin during laparoscopically assisted versus open heated intraoperative intraperitoneal chemotherapy. Ann Surg Oncol 15:3623–3624. https://doi.org/10.1245/s10434-008-0115-8 CrossRefPubMed

37.

Yonemura Y, Ishibashi H, Hirano M, Mizumoto A, Takeshita K, Noguchi K, Takao N, Ichinose M, Liu Y, Li Y (2017) Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol 24(2):478–485. https://doi.org/10.1245/s10434-016-5487-6 CrossRefPubMed

38.

Canbay E, Mizumoto A, Ichinose M et al (2015) Outcome data of patients with peritoneal carcinomatosis from gastric cancer treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol 21(4):1147–1152CrossRef

39.

Yonemura Y, Canbay E, Shintani H et al (2016) Treatment failure following complete cytoreductive surgery for peritoneal metastasis from colorectal cancer. Gan To Kagaku Ryoho 43(12):1435–1439PubMed

40.

Jichlinski P, Forre M, Mizeret J et al (1997) Clinical evaluation of a method for detecting superficial transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg Med 20:402–408CrossRefPubMed

41.

Kaneko S. Photodynamic applications (PDD, PDT) using aminolevulinic acid in neurosurgery. In: Okura I, Tanaka TR (eds) Aminolevulinic acid. Science, technology and application. SBI ALA Promo Co., Ltd, pp 119–140

42.

Rodoriguez L, Batle A, Di Verosa G et al (2006) Study of the mechanisms of uptake of 5-aminolevulinic acid derivatives by PEPT1 and PET2 transporters as a tool to improve photodynamic therapies of tumours. Int J Biochem Cell Biol 38:1530–1539CrossRef

43.

Hino H, Murayama Y, Nakanishi M, Inoue K, Nakajima M, Otsuji E (2013) 5-aminolevulinic acid-mediated photodynamic therapy using light-emitting diodes of different wavelength in a mouse model of peritoneally disseminated gastric cancer. J Surg Res 185(1):119–126. https://doi.org/10.1016/j.jss.2013.05.048 CrossRefPubMed

44.

Yonemura Y, Endo Y, Canbay E et al (2017) Photodynamic detection of peritoneal metastases using 5-aminolevulinic acid (ALA). Cancers (Basel) 9(3):E23. https://doi.org/10.3390/cancers9030023 CrossRefPubMed

45.

Hagiya Y, Furuhara H, Matsumoto K et al (2013 Sep) Expression levels of PEPT1 and ABCG2 play key roles in 5-aminolevulinic acid (ALA)-induced tumor specific protoporphyrin IX (PpIX) accumulation in bladder cancer. Photodiagn Photodyn Ther 10(3):288–295. https://doi.org/10.1016/j.pdpdt.2013.02.001 CrossRef

46.

Lőning M, Diddens H, Kűpker W et al (2004) Laparoscopic fluorescent detection of ovarian carcinoma metastasis using 5-aminolevulinic acid-induced protoporphyrin IX. Cancer 100:1650–1656CrossRefPubMed

47.

Maruyama Y, Ichikawa D, Koizumi N et al (2012) Staging fluorescence laparoscopy for gastric cancer by using 5-aminolevulinic acid. Anticancer Res 32:5421–5427

48.

Hillermans P, Wimberger P, Reif J et al (2016) Photodynamic diagnosis with 5-aminolevulinic acid for intraoperative detection of PM of ovarian cancer. A feasibility and dose finding study. Lasers Surg Med 49(2):169–176CrossRef

49.

Yonemura Y, Canbay E, Sako S, Wakama S, Ishibashi H, Hirano M, Mizumoto A, Takao N, Ichinose M, Noguchi K, Motoi S, Liu Y, Li Y, Taniguchi K (2017 Nov) Comprehensive treatment using colorectal cancer patients with metachronous peritoneal metastasis. Gan To Kagaku Ryoho 44(12):1939–1942PubMed

50.

National Institute of Health and Clinical Excellence (NICE). Cytoreduction surgery followed by hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis. IPG331. http://www.nice.org.uk/guidance/IPG331 (accessed 12 August 2013)

51.

Sugarbaker PH, Alderman R, Edwards G, Marquardt CE, Gushchin V, Esquival J et al (2005) Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 13:635–644CrossRef

52.

Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Brit J Surg 94(11):1408–1414CrossRefPubMed

53.

Huang Y, Arzahrani NA, Liauw W et al (2017) Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. ANZ J Surg 87(1–2):49–54CrossRefPubMed

54.

Bushati M, Rovers KP, Sommariva A, Sugarbaker PH, Morris DL, Yonemura Y, Quadros CA, Somashekhar SP, Ceelen W, Dubé P, Li Y, Verwaal VJ, Glehen O, Piso P, Spiliotis J, Teo MCC, González-Moreno S, Cashin PH, Lehmann K, Deraco M, Moran B, de Hingh IHJT (2018) The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol 44(12):1942–1948. https://doi.org/10.1016/j.ejso.2018.07.003 CrossRefPubMed

55.

Hamazoe R, Maeta M, Kaibara N (1994) Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 73(8):2048–2052CrossRefPubMed

56.

Yonemura Y, de Aletxabala X, Fujimura T et al (2001) Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepato-Gastroenterology 48(42):1776–1782PubMed

57.

Masuda T, Kuramoto M, Shimada S et al (2016) The effects of extensive intraoperative peritoneal lavage therapy (EIPL) in stage IIIB+C and cytology-positive gastric cancer patients. Int J Clin Oncol 21(2):289–294CrossRefPubMed

58.

Yonemura Y, Canbay E, Endou Y, Ishibashi H, Mizumoto A, Miura M, Li Y, Liu Y, Takeshita K, Ichinose M, Takao N, Hirano M, Sako S, Tsukiyama G (2014) Peritoneal cancer treatment. Expert Opin Pharmacother 15(5):623–636. https://doi.org/10.1517/14656566.2014.879571 CrossRefPubMed

Title: History of Peritoneal Surface Malignancy Treatment in Japan
Authors: Yutaka Yonemura
Shouzou Sako
Satoshi Wakama
Haruaki Ishibashi
Akiyoshi Mizumoto
Nobuyuki Takao
Masumi Ichinose
Kousuke Noguchi
Yang Liu
Syunsuke Motoi
Keizou Taniguchi
Sachio Fushida
Publication date: 01-02-2019
Publisher: Springer India
Keywords: Metastasis
Gastric Cancer
Gastric Cancer
Cytostatic Therapy
Peritonectomy
Published in: Indian Journal of Surgical Oncology / Issue Special Issue 1/2019
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-019-00893-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

History of Peritoneal Surface Malignancy Treatment in Japan

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2019

Analysis of Clinical Outcomes of Pseudomyxoma Peritonei from Appendicular Origin Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy-A Retrospective Study from INDEPSO

Failure-to-Rescue Following Cytoreductive Surgery with or Without HIPEC is Determined by the Type of Complication—a Retrospective Study by INDEPSO

Current Status of Peritoneal Surface Malignancy in Thailand

Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Pleural Malignancies—Experience from Indian Centers

Management of Peritoneal Surface Malignancies in Pakistan

Preface ‘Changing Trend in Peritoneal Surface Oncology in Asian Countries’